Tier 2 — strong

Effect of alpha-linolenic acid in combination with the flavonol quercetin on markers of cardiovascular disease risk in healthy, non-obese adults: A randomized, double-blinded placebo-controlled crossover trial

Constanze Burak, Siegfried Wolffram, Berndt Zur, Peter Langguth, Rolf Fimmers, Birgit Alteheld, Peter Stehle, Sarah Egert
Nutrition (Burbank, Los Angeles County, Calif.) 2019 58:47-56

Bibliography

PubMed
PMID 30278429
DOI
10.1016/j.nut.2018.06.012
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial
ModelHuman intervention research
Sample67 analyzed healthy adults
InterventionAlpha-linolenic acid 3.6 g/day with quercetin 190 mg/day or placebo
Duration8-week treatment periods
EndpointsBlood pressure; Lipid measurements; Inflammatory measures; Oxidative-stress measures

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover trial. Sample/model: 67 analyzed healthy adults. The exposure or intervention was Alpha-linolenic acid 3.6 g/day with quercetin 190 mg/day or placebo. Follow-up or treatment period: 8-week treatment periods.

Lipids improved similarly in both conditions, without an added quercetin effect on blood pressure, inflammation or oxidative measures.

The study did not demonstrate additive or synergistic cardiovascular benefit from adding quercetin.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Lipids improved similarly in both conditions, without an added quercetin effect on blood pressure, inflammation or oxidative measures.
  • The recorded outcome domains were Blood pressure; Lipid measurements; Inflammatory measures; Oxidative-stress measures.
  • The result applies to the tested exposure: Alpha-linolenic acid 3.6 g/day with quercetin 190 mg/day or placebo; 8-week treatment periods.

What this study can and cannot tell us

  • The study did not demonstrate additive or synergistic cardiovascular benefit from adding quercetin.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology